Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases

Source URL: www.hepatitis-schweiz.ch

• Chemistry
• Medicine
• Clinical medicine
• Breakthrough therapy
• Carbamates
• Cyclopropanes
• Infectious causes of cancer
• Sulfonamides
• Simeprevir
• Sofosbuvir
• Ombitasvir/paritaprevir/ritonavir
• Telaprevir

NIH Public Access Author Manuscript Haemophilia. Author manuscript; available in PMC 2015 September 01. NIH-PA Author Manuscript

Source URL: www.ncbi.nlm.nih.gov

• Hepatitis C virus
• Chemistry
• Cyclopropanes
• Microbiology
• Virology
• Macrocycles
• Pyrazines
• Breakthrough therapy
• Simeprevir
• NS3
• Telaprevir
• Paritaprevir

--------------------------------CONTRAINDICATIONS-----------------------------­ EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN

Source URL: www.accessdata.fda.gov

• Chemistry
• Gilead Sciences
• Medicine
• Clinical medicine
• Cyclopropanes
• Breakthrough therapy
• Combination drugs
• Organofluorides
• Sofosbuvir
• Ledipasvir
• Simeprevir
• Velpatasvir/sofosbuvir

Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases

Source URL: sasl.unibas.ch

• Clinical medicine
• Medicine
• Chemistry
• Breakthrough therapy
• Cyclopropanes
• Carbamates
• Infectious causes of cancer
• Thiazoles
• Simeprevir
• Ombitasvir/paritaprevir/ritonavir
• Sofosbuvir
• Telaprevir

Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction

Source URL: www.easl.eu

• Chemistry
• Clinical medicine
• Organic chemistry
• Breakthrough therapy
• Cyclopropanes
• Carbamates
• Gilead Sciences
• Imidazoles
• Sofosbuvir
• Simeprevir
• Ledipasvir
• Hepatitis C

TF_AITemplate_210x280_RZ.indd

Source URL: www.pcsg.org.uk

• Hepatology
• Infectious causes of cancer
• RTT
• Healthcare-associated infections
• Viral diseases
• Hepatitis C
• Hepatitis
• Liver cancer
• Sofosbuvir
• Cirrhosis
• Liver disease
• Simeprevir

NLT-gruppens yttrande till landstingen gällande nya läkemedel vid kronisk hepatit C: simeprevir (Olysio) sofosbuvir (Sovaldi) och daclatasvir (Daklinza) samt kommentar kring ledipasvir/sofosbuvir (Harvoni)

Source URL: www.janusinfo.se

Horizon Scanning Centre March 2015 Simeprevir in combination with sofosbuvir (with or without ribavirin) for chronic hepatitis C

Source URL: www.hsc.nihr.ac.uk

• Health
• Protease inhibitors
• Hepatology
• Viral hepatitis
• Cytokines
• Hepatitis
• Boceprevir
• Telaprevir
• Peginterferon alfa-2a
• Medicine
• Antivirals
• Biology

Interim Clinical Commissioning Policy Statement: Simeprevir for treating Genotype 1 Chronic Hepatitis C Reference: NHS England A02/PS/c

Source URL: www.england.nhs.uk

• Pharmacology
• Biology
• Hepatology
• Hepatitis
• Pyrazines
• Telaprevir
• Boceprevir
• Peginterferon alfa-2a
• Hepatitis C
• Medicine
• Antivirals
• Protease inhibitors

® OLYSIO Capsules simeprevir Consumer Medicine Information

Source URL: www.janssen.com.au

• Ribavirin
• Triazoles
• Microbiology
• Pharmacology
• Boceprevir
• Telaprevir
• Interferon
• Hepatitis C
• Pharmaceutical drug
• Protease inhibitors
• Antivirals
• Medicine